XTX Topco Ltd Invests $1.11 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

XTX Topco Ltd acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,151 shares of the company's stock, valued at approximately $1,113,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Barclays PLC lifted its holdings in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock valued at $5,552,000 after purchasing an additional 45,509 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock worth $81,659,000 after acquiring an additional 23,564 shares in the last quarter. Franklin Resources Inc. grew its position in Axsome Therapeutics by 47.5% during the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock worth $13,713,000 after acquiring an additional 51,696 shares during the last quarter. JPMorgan Chase & Co. raised its position in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after purchasing an additional 27,534 shares during the last quarter. Finally, Pallas Capital Advisors LLC acquired a new position in Axsome Therapeutics in the fourth quarter worth $2,237,000. 81.49% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Stock Down 1.4 %

Shares of AXSM stock traded down $1.44 on Monday, hitting $103.02. 125,732 shares of the stock were exchanged, compared to its average volume of 678,164. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The firm has a market capitalization of $5.02 billion, a P/E ratio of -17.20 and a beta of 0.88. The business has a 50-day moving average of $118.16 and a 200 day moving average of $102.54.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AXSM shares. Needham & Company LLC reissued a "buy" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Wells Fargo & Company upped their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Finally, Robert W. Baird lifted their target price on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $169.80.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.